Loading
NB003 is an experimental small-molecule drug from Ningbo Newbay Technology Development in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.
NB003 is a small-molecule drug developed by Ningbo Newbay Technology Development. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 15 mg BID on a continuous schedule in 28-day cycles. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07379047 (Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumours (GIST)), in gastrointestinal stromal tumour. The largest, NCT07379047, plans to enrol 255 participants with primary completion expected 2028-08-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.NB003 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NB003" OR ABSTRACT:"NB003") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NB003, not a curated reading list.
Shares KIT exon 11-mutant GIST, Imatinib-resistant GIST, Gastrointestinal stromal tumour (GIST) and the tag pipeline.
Shares Imatinib-resistant GIST, Gastrointestinal stromal tumour (GIST) and the tag pipeline.
Shares KIT exon 11-mutant GIST, Imatinib-resistant GIST, Gastrointestinal stromal tumour (GIST) and the tag pipeline.
Shares Gastrointestinal stromal tumour (GIST) and the tag pipeline.
Shares Gastrointestinal stromal tumour (GIST) and the tag pipeline.
Shares Imatinib-resistant GIST, Gastrointestinal stromal tumour (GIST).
Shares Imatinib-resistant GIST, Gastrointestinal stromal tumour (GIST).
Shares KIT exon 11-mutant GIST, Gastrointestinal stromal tumour (GIST).